Kinmenlin Approves Non-Compete Waiver for Six New Directors at Shareholder Meeting
Kinmenlin approved the waiver of non-compete obligations for six newly appointed directors at the annual general meeting on May 22, 2026, stating no material financial impact.
📋 Article Processing Timeline
- 📰 Published: May 22, 2026 at 09:00
- 🔍 Collected: May 23, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 24, 2026 at 05:59 (21h 59m after Collected)
1. Date of shareholders' meeting resolution: May 22, 2026
2. Names and titles of directors permitted to engage in competitive activities:
(1) Wu Pin-tsung, Director
(2) Chen Hui-e, Director
(3) Wu Pin-hsiang, Director
(4) Hung Ying-ju, Director
(5) Chen Chien-yu, Director
(6) Lu Chih-yi, Independent Director
3. Items for which competitive behavior is permitted:
(1) Wu Pin-tsung, Director: Director, Yuan Cui Data Technology Co., Ltd.
(2) Chen Hui-e, Director: Director, Yuan Cui Data Technology Co., Ltd.; Independent Director, Beili Biotech Venture Capital Co., Ltd.
(3) Wu Pin-hsiang, Director: Director, Yuan Cui Data Technology Co., Ltd.
(4) Hung Ying-ju, Director: Director, Yuan Cui Data Technology Co., Ltd.
(5) Chen Chien-yu, Director: Person-in-charge, AEBRLOS GENOMICS INC
(6) Lu Chih-yi, Independent Director: Director, Oji Pharmaceutical Co., Ltd.
4. Period for which competitive behavior is permitted: During their term of office as a director of the Company
5. Resolution status (Voting results under Article 209 of the Company Act): Passed as proposed
6. Whether the permitted competitive activities involve operations in mainland China: Not applicable
7. Name and position in mainland China business: Not applicable
8. Address of mainland China business: Not applicable
9. Business scope of mainland China business: Not applicable
10. Impact on the company's financial operations: No material impact
11. Investment and shareholding ratio if a director invests in mainland China business: None
12. Other matters: None
2. Names and titles of directors permitted to engage in competitive activities:
(1) Wu Pin-tsung, Director
(2) Chen Hui-e, Director
(3) Wu Pin-hsiang, Director
(4) Hung Ying-ju, Director
(5) Chen Chien-yu, Director
(6) Lu Chih-yi, Independent Director
3. Items for which competitive behavior is permitted:
(1) Wu Pin-tsung, Director: Director, Yuan Cui Data Technology Co., Ltd.
(2) Chen Hui-e, Director: Director, Yuan Cui Data Technology Co., Ltd.; Independent Director, Beili Biotech Venture Capital Co., Ltd.
(3) Wu Pin-hsiang, Director: Director, Yuan Cui Data Technology Co., Ltd.
(4) Hung Ying-ju, Director: Director, Yuan Cui Data Technology Co., Ltd.
(5) Chen Chien-yu, Director: Person-in-charge, AEBRLOS GENOMICS INC
(6) Lu Chih-yi, Independent Director: Director, Oji Pharmaceutical Co., Ltd.
4. Period for which competitive behavior is permitted: During their term of office as a director of the Company
5. Resolution status (Voting results under Article 209 of the Company Act): Passed as proposed
6. Whether the permitted competitive activities involve operations in mainland China: Not applicable
7. Name and position in mainland China business: Not applicable
8. Address of mainland China business: Not applicable
9. Business scope of mainland China business: Not applicable
10. Impact on the company's financial operations: No material impact
11. Investment and shareholding ratio if a director invests in mainland China business: None
12. Other matters: None
FAQ
Why is it necessary to waive the non-compete obligation?
Under corporate law, when a director holds a position in another company, approval from the shareholders' meeting is required to prevent potential conflicts of interest.
Is this resolution common?
Yes, it is a standard corporate governance procedure in Taiwan when hiring experts who hold positions in multiple entities.
What risks should be monitored?
Investors should monitor whether potential conflicts of interest or overlaps in professional duties are being properly managed.